Recent Updates
Recently added Catalysts
RCUS Positive Sentiment

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Key Takeaway: Arcus Biosciences will participate in two investor conferences in December 2026. The events include the 8th Annual Evercore Healthcare Conference and Citi's 2026 Global Healthcare Conference. Management will engage in fireside chats and 1x1 meetings, with live webcasts available on their website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in major investor conferences.
  • Opportunity for 1x1 meetings with management.
  • Focus on innovative cancer therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
2.8%
average across 10 past catalysts
Cash runway
~23 mo
Low dilution risk
Lead asset
Etrumadenant
Phase 2 · Prostatic Neoplasms, Castration-Resistant

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and immune diseases, announced that its management team will participate in the following upcoming investor conferences in December:
8th Annual Evercore Healthcare Conference Date: Tuesday, December 1st, 2026 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 3:50 p.m. ET
Citi’s 2026 Global Healthcare Conference Date: Wednesday, December 2nd, 2026 Location: Miami, FL Format: Fireside chat & 1x1 meetings Time: 2:20 p.m. ET
Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases. Founded in 2015, Arcus pairs proven biology with exceptional chemistry to create medicines that deliver meaningful improvements for patients. The company has advanced two oncology programs to Phase 3 clinical trials, including casdatifan, a HIF-2α inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. Arcus is also applying its small-molecule, medicinal chemistry and antibody capabilities to expand into immunology. Every program is held to the highest standard: outperform the current standard of care. For more information about Arcus Biosciences' clinical and preclinical programs, please visit www.arcusbio.com.

Frequently Asked Questions

When will Arcus Biosciences participate in investor conferences?

Arcus will participate on December 1st and 2nd, 2026.

Where are the upcoming conferences located?

The conferences will be in Coral Gables, FL, and Miami, FL.

What formats will the conferences include?

The conferences will feature fireside chats and 1x1 meetings.

Will the events be available for online viewing?

Yes, live webcasts will be available on their website.

Last updated: Nov 18, 2026